SCHEMBL975342

SCHEMBL975342

CCOC(=O)c1cn2ccc(Br)cc2n1

nearest known ligand 0.76

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.76
POLB P06746 1/20 0.76
GAA P10253 1/20 0.51
ALDH1A1 P00352 2/20 0.50
HPGD P15428 1/20 0.50
SMN1; SMN2 Q16637 2/20 0.48
RAB9A P51151 5/20 0.47
MAPT P10636 1/20 0.47
CYP1A2 P05177 1/20 0.45
GABRA2 P47869 3/20 0.45
GABRB2 P47870 3/20 0.45
NPC1 O15118 3/20 0.44
RXFP1 Q9HBX9 1/20 0.44
KMT2A Q03164 1/20 0.44
GABRG2 P18507 1/20 0.43
GABRB3 P28472 1/20 0.43
GABRA5 P31644 1/20 0.43
METTL3 Q86U44 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1445451 0.86 KDM4E (1.00) KDM4EPOLBGAAALDH1A1HPGD
SCHEMBL7269185 0.85 KDM4E (0.78) KDM4EPOLBGAAALDH1A1HPGD
SCHEMBL17437886 0.85 KDM4E (0.78) KDM4EPOLBGAAALDH1A1HPGD
SCHEMBL20602411 0.85 KDM4E (0.53) KDM4EPOLBGAAALDH1A1SMN1; SMN2
SCHEMBL15767159 0.84 KDM4E (0.76) KDM4EPOLBGAAALDH1A1HPGD
SCHEMBL1647902 0.84 KDM4E (0.76) KDM4EPOLBGAAALDH1A1HPGD
SCHEMBL16691126 0.84 KDM4E (0.76) KDM4EPOLBGAAALDH1A1HPGD
SCHEMBL22148188 0.83 KDM4E (0.74) KDM4EPOLBGAAALDH1A1HPGD
SCHEMBL15744771 0.83 KDM4E (0.74) KDM4EPOLBGAAALDH1A1HPGD
SCHEMBL4352501 0.83 KDM4E (0.74) KDM4EPOLBGAAALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4701635-A1 1,2,4-TRIAZOLE-3-THIONE INHIBITORS OF TREX2 FOR USE IN THE TREATMENT OF PSORIASIS, ATOPIC DERMATITIS OR ICHTHYOSIS Universitat De Barcelona (ES) 2026-03-04 EP disclosed
WO-2025215082-A1 FUSED AZINES FOR THE TREATMENT OF INFLAMMATORY DISEASES GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2025-10-16 WO disclosed
WO-2025077671-A1 POLYSUBSTITUTED ARYL DERIVATIVE AND PREPARATION METHOD THEREFOR AND USE THEREOF 浙江海正药业股份有限公司 2025-04-17 WO disclosed
WO-2024223907-A1 1,2,4-TRIAZOLE-3-THIONE INHIBITORS OF TREX2 FOR USE IN THE TREATMENT OF PSORIASIS, ATOPIC DERMATITIS OR ICHTHYOSIS UNIVERSITAT DE BARCELONA (ES) 2024-10-31 WO disclosed
WO-2024218059-A1 NEW α4β7 INHIBITORS EVOTEC INTERNATIONAL GMBH (DE) 2024-10-24 WO disclosed
US-12037339-B2 Substituted imidazoles as GLP-1 receptor agonists ECCOGENE INC. (US) 2024-07-16 US disclosed
US-12037339-B2 Substituted imidazoles as GLP-1 receptor agonists ECCOGENE INC. (US) 2024-07-16 US disclosed
US-20240156780-A1 TLR2 MODULATOR COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF AXIAL THERAPEUTICS, INC. (US) 2024-05-16 US disclosed
US-11951094-B2 TLR2 modulator compounds, pharmaceutical compositions and uses thereof AXIAL THERAPEUTICS, INC. (US) 2024-04-09 US disclosed
EP-4171547-A1 TLR2 MODULATOR COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF Axial Therapeutics, Inc. (US) 2023-05-03 EP disclosed
US-20130237502-A1 PHENICOL ANTIBACTERIALS ZOETIS SERVICES LLC 2013-09-12 US disclosed
US-20130237502-A1 PHENICOL ANTIBACTERIALS ZOETIS SERVICES LLC 2013-09-12 US disclosed
US-20130237502-A1 PHENICOL ANTIBACTERIALS ZOETIS SERVICES LLC 2013-09-12 US disclosed
US-8394820-B2 N-azabicyclic carboxamide derivatives, preparation thereof and therapeutic use thereof SANOFI (FR) 2013-03-12 US disclosed
US-8394820-B2 N-azabicyclic carboxamide derivatives, preparation thereof and therapeutic use thereof SANOFI (FR) 2013-03-12 US disclosed
US-8394820-B2 N-azabicyclic carboxamide derivatives, preparation thereof and therapeutic use thereof SANOFI (FR) 2013-03-12 US disclosed
US-20110009444-A1 N-AZABICYCLIC CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2011-01-13 US disclosed
US-20110009444-A1 N-AZABICYCLIC CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2011-01-13 US disclosed
US-20110009444-A1 N-AZABICYCLIC CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2011-01-13 US disclosed
WO-2009112679-A1 AZABICYCLIC CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2009-09-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130237502-A1 PHENICOL ANTIBACTERIALS MRPL21, TTL, CTSL KDM4E 583/4885POLB 1238/4885GAA 2559/4885
US-12037339-B2 Substituted imidazoles as GLP-1 receptor agonists GLP1R, GIPR, SLC5A1 KDM4E 4189/4885POLB 4735/4885GAA 2310/4885
US-20240156780-A1 TLR2 MODULATOR COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF TLR2, TLR3, TLR4 KDM4E 4292/4885POLB 3275/4885GAA 2469/4885
US-11951094-B2 TLR2 modulator compounds, pharmaceutical compositions and uses thereof TLR2, TLR3, TLR4 KDM4E 4292/4885POLB 3275/4885GAA 2469/4885
US-20110009444-A1 N-AZABICYCLIC CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF XDH, NQO2, SLC28A2 KDM4E 246/4885POLB 960/4885GAA 547/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.